Back

The complete bioavailability of asundexian is unaffected by tablet formulation, gastric pH or food

29 August 2022 (08:15 - 09:00)
Organised by:
Congress Presentation Part of: Vascular biology and physiology Drugs, Drug Targets ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Friederike Kanefendt

Bayer AG, Wuppertal (Germany)

5 More presentations in this session

Presentation thumbnail
Circadian nuclear receptor Rev-erbalpha is expressed by platelets and potentiates platelet activation and thrombus formation
Doctor J. Shi (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Arterial thrombosis in Hutchinson Gilford Progeria Syndrome
Doctor Y. Puspitasari (Schlieren, CH)
Abstract Slides
Presentation thumbnail
SGLT-2 inhibition by empagliflozin exerts neutral effects on experimental arterial thrombosis in a murine model of low-grade inflammation
Assistant Professor L. Liberale (Genova, IT)
Abstract Slides
Presentation thumbnail
Fast and more affordable CYP2C19 LOF testing to personalized of clopidogrel therapy
Doctor M. Sheikh Abdul Kader (Serdang, MY)
Abstract Slides
Presentation thumbnail
Effect of coagulation factors FXIa, FXIIa, F alpha-XIIa, F beta-XIIa and FXIIIa on platelet function
Mrs L. Wildeis (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Vascular biology and physiology

The Event

Event poster

ESC Congress 2022

29 August 2022 08:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources